Loading…

NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas

Abstract Background: Recent study suggests that “T2/FLAIR mismatch” sign is specific MRI finding for isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted gliomas (Grade II and III astrocytic tumors). T2/FLAIR mismatch sign may be useful for predicting the histological type of glioma before...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology advances 2020-11, Vol.2 (Supplement_3), p.ii13-ii14
Main Authors: Ebiko, Yusuke, Tamura, Kaoru, Hara, Shoko, Inaji, Motoki, Tanaka, Yoji, Nariai, Tadashi, Ishii, Kenji, Maehara, Taketoshi
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page ii14
container_issue Supplement_3
container_start_page ii13
container_title Neuro-oncology advances
container_volume 2
creator Ebiko, Yusuke
Tamura, Kaoru
Hara, Shoko
Inaji, Motoki
Tanaka, Yoji
Nariai, Tadashi
Ishii, Kenji
Maehara, Taketoshi
description Abstract Background: Recent study suggests that “T2/FLAIR mismatch” sign is specific MRI finding for isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted gliomas (Grade II and III astrocytic tumors). T2/FLAIR mismatch sign may be useful for predicting the histological type of glioma before surgery. However, it is not known what this finding reflects. Therefore, we examined the correlation between T2/FLAIR mismatch sign and uptake of methionine with positron emission tomography (MET-PET), and molecular classification of glioma. Methods: 74 glioma patients (grade II: 30 cases, grade III: 44 cases) with preoperative MRI and MET-PET who underwent surgical resection during 2000–2019 were included in this study. MR scans were evaluated by 3 independent reviewers to assess presence/absence of T2/FLAIR mismatch sign. The tumor-to-normal (T/N) ratio of methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. We examined the relationship between IDH mutation, 1p/19q codeletion, mismatch, and T/N ratio of MET-PET. Results: Out of the 74 cases, astrocytic tumors (A group: IDH-mutant, 1p19q non-codeleted) were 21 (28%), oligodendroglial tumors (O group: IDH-mutant, 1p19q codeleted) were 19 (26%), and IDH wild tumors (W group) were 34 (46%). The T2/FLAIR mismatch sign was present in 16 cases (22%). The T/N ratio of MET-PET in the tumor with T2/FLAIR mismatch sign was 1.56, which was significantly lower than that in the tumor without mismatch sign (2.01, p=0.016). T2/FLAIR mismatch sign was found in 7 (33%) cases in the A group, 0 (0%) case in the O group and 9 (26%) cases in the W group, and the positive rate was significantly higher in the A group (p=0.013). Conclusions: “T2/FLAIR mismatch” sign was a specific finding for astrocytic tumor, and the cases with positive “T2/FLAIR mismatch” sign had significantly lower MET-PET uptake than that with negative cases.
doi_str_mv 10.1093/noajnl/vdaa143.058
format article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7699068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/noajnl/vdaa143.058</oup_id><sourcerecordid>10.1093/noajnl/vdaa143.058</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1808-170efea15bdc7e1582ebb9706a506e0a27770b2e495c4f667a7a0a53af7cf9cd3</originalsourceid><addsrcrecordid>eNqNkMFKw0AURQdRsNT-gKv5gbRvJplMshFKaTVQVEpdDy_JJJ2aTEImLfj3RlNEd67ug3fvWRxC7hnMGcT-wjZ4tNXinCOywJ-DiK7IhIc-93gQR9e_7lsyc-4IAFwEIgA-IbvnxGNA93yx2S6THa2Nq7HPDtSZ0lK0Oa11fzCNNVbT1_Wentoe3zU1lpYd5pomyXcrGbKsTFOjuyM3BVZOzy45JW-b9X715G1fHpPVcutlLILIYxJ0oZGJNM-kZiLiOk1jCSEKCDUgl1JCynUQiywowlCiREDhYyGzIs5yf0oeRm57SmudZ9r2HVaq7UyN3Ydq0Ki_H2sOqmzOSoZxDGE0APgIyLrGuU4XP1sG6susGs2qi1k1mB1G3jhqTu1_-p_TIX2N</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas</title><source>PubMed Central</source><source>Oxford Open Access Journals</source><creator>Ebiko, Yusuke ; Tamura, Kaoru ; Hara, Shoko ; Inaji, Motoki ; Tanaka, Yoji ; Nariai, Tadashi ; Ishii, Kenji ; Maehara, Taketoshi</creator><creatorcontrib>Ebiko, Yusuke ; Tamura, Kaoru ; Hara, Shoko ; Inaji, Motoki ; Tanaka, Yoji ; Nariai, Tadashi ; Ishii, Kenji ; Maehara, Taketoshi</creatorcontrib><description>Abstract Background: Recent study suggests that “T2/FLAIR mismatch” sign is specific MRI finding for isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted gliomas (Grade II and III astrocytic tumors). T2/FLAIR mismatch sign may be useful for predicting the histological type of glioma before surgery. However, it is not known what this finding reflects. Therefore, we examined the correlation between T2/FLAIR mismatch sign and uptake of methionine with positron emission tomography (MET-PET), and molecular classification of glioma. Methods: 74 glioma patients (grade II: 30 cases, grade III: 44 cases) with preoperative MRI and MET-PET who underwent surgical resection during 2000–2019 were included in this study. MR scans were evaluated by 3 independent reviewers to assess presence/absence of T2/FLAIR mismatch sign. The tumor-to-normal (T/N) ratio of methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. We examined the relationship between IDH mutation, 1p/19q codeletion, mismatch, and T/N ratio of MET-PET. Results: Out of the 74 cases, astrocytic tumors (A group: IDH-mutant, 1p19q non-codeleted) were 21 (28%), oligodendroglial tumors (O group: IDH-mutant, 1p19q codeleted) were 19 (26%), and IDH wild tumors (W group) were 34 (46%). The T2/FLAIR mismatch sign was present in 16 cases (22%). The T/N ratio of MET-PET in the tumor with T2/FLAIR mismatch sign was 1.56, which was significantly lower than that in the tumor without mismatch sign (2.01, p=0.016). T2/FLAIR mismatch sign was found in 7 (33%) cases in the A group, 0 (0%) case in the O group and 9 (26%) cases in the W group, and the positive rate was significantly higher in the A group (p=0.013). Conclusions: “T2/FLAIR mismatch” sign was a specific finding for astrocytic tumor, and the cases with positive “T2/FLAIR mismatch” sign had significantly lower MET-PET uptake than that with negative cases.</description><identifier>ISSN: 2632-2498</identifier><identifier>EISSN: 2632-2498</identifier><identifier>DOI: 10.1093/noajnl/vdaa143.058</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Supplement Abstracts</subject><ispartof>Neuro-oncology advances, 2020-11, Vol.2 (Supplement_3), p.ii13-ii14</ispartof><rights>The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699068/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699068/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Ebiko, Yusuke</creatorcontrib><creatorcontrib>Tamura, Kaoru</creatorcontrib><creatorcontrib>Hara, Shoko</creatorcontrib><creatorcontrib>Inaji, Motoki</creatorcontrib><creatorcontrib>Tanaka, Yoji</creatorcontrib><creatorcontrib>Nariai, Tadashi</creatorcontrib><creatorcontrib>Ishii, Kenji</creatorcontrib><creatorcontrib>Maehara, Taketoshi</creatorcontrib><title>NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas</title><title>Neuro-oncology advances</title><description>Abstract Background: Recent study suggests that “T2/FLAIR mismatch” sign is specific MRI finding for isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted gliomas (Grade II and III astrocytic tumors). T2/FLAIR mismatch sign may be useful for predicting the histological type of glioma before surgery. However, it is not known what this finding reflects. Therefore, we examined the correlation between T2/FLAIR mismatch sign and uptake of methionine with positron emission tomography (MET-PET), and molecular classification of glioma. Methods: 74 glioma patients (grade II: 30 cases, grade III: 44 cases) with preoperative MRI and MET-PET who underwent surgical resection during 2000–2019 were included in this study. MR scans were evaluated by 3 independent reviewers to assess presence/absence of T2/FLAIR mismatch sign. The tumor-to-normal (T/N) ratio of methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. We examined the relationship between IDH mutation, 1p/19q codeletion, mismatch, and T/N ratio of MET-PET. Results: Out of the 74 cases, astrocytic tumors (A group: IDH-mutant, 1p19q non-codeleted) were 21 (28%), oligodendroglial tumors (O group: IDH-mutant, 1p19q codeleted) were 19 (26%), and IDH wild tumors (W group) were 34 (46%). The T2/FLAIR mismatch sign was present in 16 cases (22%). The T/N ratio of MET-PET in the tumor with T2/FLAIR mismatch sign was 1.56, which was significantly lower than that in the tumor without mismatch sign (2.01, p=0.016). T2/FLAIR mismatch sign was found in 7 (33%) cases in the A group, 0 (0%) case in the O group and 9 (26%) cases in the W group, and the positive rate was significantly higher in the A group (p=0.013). Conclusions: “T2/FLAIR mismatch” sign was a specific finding for astrocytic tumor, and the cases with positive “T2/FLAIR mismatch” sign had significantly lower MET-PET uptake than that with negative cases.</description><subject>Supplement Abstracts</subject><issn>2632-2498</issn><issn>2632-2498</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkMFKw0AURQdRsNT-gKv5gbRvJplMshFKaTVQVEpdDy_JJJ2aTEImLfj3RlNEd67ug3fvWRxC7hnMGcT-wjZ4tNXinCOywJ-DiK7IhIc-93gQR9e_7lsyc-4IAFwEIgA-IbvnxGNA93yx2S6THa2Nq7HPDtSZ0lK0Oa11fzCNNVbT1_Wentoe3zU1lpYd5pomyXcrGbKsTFOjuyM3BVZOzy45JW-b9X715G1fHpPVcutlLILIYxJ0oZGJNM-kZiLiOk1jCSEKCDUgl1JCynUQiywowlCiREDhYyGzIs5yf0oeRm57SmudZ9r2HVaq7UyN3Ydq0Ki_H2sOqmzOSoZxDGE0APgIyLrGuU4XP1sG6susGs2qi1k1mB1G3jhqTu1_-p_TIX2N</recordid><startdate>20201128</startdate><enddate>20201128</enddate><creator>Ebiko, Yusuke</creator><creator>Tamura, Kaoru</creator><creator>Hara, Shoko</creator><creator>Inaji, Motoki</creator><creator>Tanaka, Yoji</creator><creator>Nariai, Tadashi</creator><creator>Ishii, Kenji</creator><creator>Maehara, Taketoshi</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20201128</creationdate><title>NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas</title><author>Ebiko, Yusuke ; Tamura, Kaoru ; Hara, Shoko ; Inaji, Motoki ; Tanaka, Yoji ; Nariai, Tadashi ; Ishii, Kenji ; Maehara, Taketoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1808-170efea15bdc7e1582ebb9706a506e0a27770b2e495c4f667a7a0a53af7cf9cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Supplement Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebiko, Yusuke</creatorcontrib><creatorcontrib>Tamura, Kaoru</creatorcontrib><creatorcontrib>Hara, Shoko</creatorcontrib><creatorcontrib>Inaji, Motoki</creatorcontrib><creatorcontrib>Tanaka, Yoji</creatorcontrib><creatorcontrib>Nariai, Tadashi</creatorcontrib><creatorcontrib>Ishii, Kenji</creatorcontrib><creatorcontrib>Maehara, Taketoshi</creatorcontrib><collection>Oxford Open Access Journals</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebiko, Yusuke</au><au>Tamura, Kaoru</au><au>Hara, Shoko</au><au>Inaji, Motoki</au><au>Tanaka, Yoji</au><au>Nariai, Tadashi</au><au>Ishii, Kenji</au><au>Maehara, Taketoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas</atitle><jtitle>Neuro-oncology advances</jtitle><date>2020-11-28</date><risdate>2020</risdate><volume>2</volume><issue>Supplement_3</issue><spage>ii13</spage><epage>ii14</epage><pages>ii13-ii14</pages><issn>2632-2498</issn><eissn>2632-2498</eissn><abstract>Abstract Background: Recent study suggests that “T2/FLAIR mismatch” sign is specific MRI finding for isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted gliomas (Grade II and III astrocytic tumors). T2/FLAIR mismatch sign may be useful for predicting the histological type of glioma before surgery. However, it is not known what this finding reflects. Therefore, we examined the correlation between T2/FLAIR mismatch sign and uptake of methionine with positron emission tomography (MET-PET), and molecular classification of glioma. Methods: 74 glioma patients (grade II: 30 cases, grade III: 44 cases) with preoperative MRI and MET-PET who underwent surgical resection during 2000–2019 were included in this study. MR scans were evaluated by 3 independent reviewers to assess presence/absence of T2/FLAIR mismatch sign. The tumor-to-normal (T/N) ratio of methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. We examined the relationship between IDH mutation, 1p/19q codeletion, mismatch, and T/N ratio of MET-PET. Results: Out of the 74 cases, astrocytic tumors (A group: IDH-mutant, 1p19q non-codeleted) were 21 (28%), oligodendroglial tumors (O group: IDH-mutant, 1p19q codeleted) were 19 (26%), and IDH wild tumors (W group) were 34 (46%). The T2/FLAIR mismatch sign was present in 16 cases (22%). The T/N ratio of MET-PET in the tumor with T2/FLAIR mismatch sign was 1.56, which was significantly lower than that in the tumor without mismatch sign (2.01, p=0.016). T2/FLAIR mismatch sign was found in 7 (33%) cases in the A group, 0 (0%) case in the O group and 9 (26%) cases in the W group, and the positive rate was significantly higher in the A group (p=0.013). Conclusions: “T2/FLAIR mismatch” sign was a specific finding for astrocytic tumor, and the cases with positive “T2/FLAIR mismatch” sign had significantly lower MET-PET uptake than that with negative cases.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/noajnl/vdaa143.058</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2632-2498
ispartof Neuro-oncology advances, 2020-11, Vol.2 (Supplement_3), p.ii13-ii14
issn 2632-2498
2632-2498
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7699068
source PubMed Central; Oxford Open Access Journals
subjects Supplement Abstracts
title NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T03%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NI-10%20T2/FLAIR%20mismatch%20sign%20and%20methionine%20PET%20uptake%20in%20grade%20II%20and%20III%20gliomas&rft.jtitle=Neuro-oncology%20advances&rft.au=Ebiko,%20Yusuke&rft.date=2020-11-28&rft.volume=2&rft.issue=Supplement_3&rft.spage=ii13&rft.epage=ii14&rft.pages=ii13-ii14&rft.issn=2632-2498&rft.eissn=2632-2498&rft_id=info:doi/10.1093/noajnl/vdaa143.058&rft_dat=%3Coup_pubme%3E10.1093/noajnl/vdaa143.058%3C/oup_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1808-170efea15bdc7e1582ebb9706a506e0a27770b2e495c4f667a7a0a53af7cf9cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/noajnl/vdaa143.058&rfr_iscdi=true